Nevertheless, if this paradigm, based on IL-8/KC, were applicable to other inflammatory mediators and human asthma and COPD, TRPA1 could represent a highly needed novel target, and TRPA1 antagonists might be regarded as novel medicines, for the treatment of inflammatory respiratory diseases by targeting not only the channel expressed in sensory nerve terminals to reduce cough [48], [57], but, more importantly, in resident non-neuronal cells to limit inflammation in airway and lung tissue. The gene discussed is TRPA1; the disease is asthma.